Fractyl Health (GUTS): $4.80 Consensus Target Points to +790% Upside
Key Takeaways
- The central target of $4.80 is the arithmetic mean of five attributable analyst price targets, with an unusually wide range from $2.00 to $8.00.
- Shares of Fractyl Health, Inc. (GUTS) recently traded near $0.54, meaning reaching $4.80 would require a rise of roughly 790% — a very large move.
- Bullish targets rest on the Revita procedure's potential in the large GLP-1 discontinuation market and on the Rejuva gene-therapy platform.
- The biggest risks are a finite cash runway, possible dilution, durability and reimbursement questions, and intense competition from established GLP-1 drugmakers.
- The next key catalyst is six-month pivotal Revita data, expected in the fourth quarter of 2026.
Analyst Price Targets and Consensus View
Fractyl Health, Inc. is a clinical-stage metabolic-disease company developing the Revita procedure (an endoscopic duodenal mucosal resurfacing treatment) and Rejuva, a GLP-1-based gene-therapy platform. Five current, attributable price targets were reviewed, and their mean is $4.80. The range is wide: Morgan Stanley holds a $2.00 target, Bank of America Securities carries $2.00, Craig-Hallum is at $4.00, and both Canaccord Genuity and H.C. Wainwright maintain $8.00 targets.
That spread — from $2.00 to $8.00 — reflects genuine disagreement about execution risk and the commercial opportunity rather than a simple margin of error. The most cautious views sit around $2.00, roughly four times the recent price, while the most bullish targets near $8.00 embed successful pivotal data and meaningful traction in weight maintenance after patients stop GLP-1 therapies. H.C. Wainwright's Joseph Pantginis reiterated a Buy with an $8.00 target, and Craig-Hallum's Chase Knickerbocker initiated coverage with a Buy and a $4.00 target in mid-2026, framing valuation around the GLP-1 discontinuation funnel. Some aggregators report slightly higher averages because they include additional or differently dated targets, but the $4.80 mean reflects the five clearly attributable targets reviewed here. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
After trading near $0.90 in mid-2026, shares have slid to roughly $0.54, leaving the company with a market capitalization of only about $54 million. Reaching $4.80 would therefore require a gain of approximately 790% — a very large move by any standard, even for a clinical-stage biotech. The path would almost certainly depend on a decisive, positive pivotal readout that meaningfully de-risks the Revita program, followed by a financing or partnership that extends the company's cash runway without excessive dilution.
What Could Support a Move Toward the Target
Analysts framing upside point to the scale of the GLP-1 discontinuation market: large numbers of U.S. adults take GLP-1 drugs, and a substantial share stop within the first year, creating a potential need for durable weight maintenance. If six-month pivotal Revita data in the fourth quarter show durable benefit after discontinuation, the bear-case thesis could weaken quickly. The Rejuva platform, including the RJVA-001 candidate entering the clinic, represents a second, longer-dated growth pillar. The company also reported a modest quarterly net profit in early 2026 versus a prior-year loss, and recent insider buying has signaled some confidence internally. From what I see, this setup warrants close monitoring of the upcoming data.
What Could Prevent the Target From Being Reached
The principal obstacle is financial and clinical. Fractyl has a finite cash runway, and a capital raise at current prices would be highly dilutive to existing holders. Revita's commercial viability still depends on demonstrating real-world durability, securing reimbursement, and competing against entrenched GLP-1 leaders such as Eli Lilly and Novo Nordisk. If the pivotal data disappoint or show only short-lived benefit, the higher targets of $4.00 and $8.00 would be difficult to justify, and the stock could remain under pressure. Regulatory and execution risk around the Rejuva gene-therapy program adds further uncertainty.
Technical Levels and Market Structure
Technical analysis offers limited guidance for a stock that has fallen from its early-2024 IPO levels to well below $1.00. The $1.00 mark now functions as a psychological resistance level, and any sustained recovery would first need to reclaim that zone before the multi-dollar analyst targets become technically relevant. Because shares trade far beneath their prior highs, classic support levels from earlier trading ranges no longer apply to the current price structure.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may apply different assumptions. The most important near-term items are the six-month pivotal Revita data expected in the fourth quarter of 2026, any updates on the Rejuva RJVA-001 clinical entry, financing announcements, and subsequent analyst revisions. Cash-runway disclosures and any dilution are equally critical, because they directly affect how much of the modeled upside can survive at the share level. I’m watching this closely for any shifts in momentum.
Final Assessment
The central $4.80 target is the mean of five attributable analyst targets spanning $2.00 to $8.00, and it sits roughly 790% above the recent price near $0.54. The wide range reflects deep disagreement about whether Revita can convert a large GLP-1 discontinuation opportunity into durable, reimbursed revenue, and whether the company's cash runway can support the journey. Positive fourth-quarter pivotal data and a non-dilutive financing would materially strengthen the path toward the target, while weak durability data or heavy dilution would make the higher estimates difficult to sustain. Investors should focus on the pivotal readout, financing decisions, and subsequent analyst revisions rather than treating the mean target as a guarantee.
Using AI Daily Buy/Sell Signals for Catalyst-Driven Names
One tool I find useful in my own research for tracking volatile names like this is Tickeron’s AI Daily Buy/Sell Signals. It applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold indications based on shifting market conditions and technical behavior. For a catalyst-driven stock such as GUTS, these signals can help identify emerging trends more efficiently than manual review alone, supporting decisions around momentum and position management.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GUTS's RSI Oscillator recovers from oversold territory
The RSI Oscillator for GUTS moved out of oversold territory on September 29, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 21 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 27 of 28 cases where GUTS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +15.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where GUTS advanced for three days, in 104 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
GUTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GUTS as a result. In 37 of 43 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for GUTS turned negative on September 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 20 similar instances when the indicator turned negative. In 17 of the 20 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
GUTS moved below its 50-day moving average on August 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GUTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GUTS entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. GUTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.133) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. GUTS's P/S Ratio (10000.000) is very high in comparison to the industry average of (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GUTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology